Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.620
+0.170 (3.82%)
Jan 17, 2025, 4:00 PM EST - Market closed
Company Description
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases.
Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders.
Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Camp4 Therapeutics Corporation
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 11, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Joshua Mandel-Brehm |
Contact Details
Address: One Kendall Square, Building 1400 West Cambridge, Massachusetts 02139 United States | |
| Phone | (617) 651-8867 |
| Website | camp4tx.com |
Stock Details
| Ticker Symbol | CAMP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001736730 |
| CUSIP Number | 13463J101 |
| ISIN Number | US13463J1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joshua Mandel-Brehm | Chief Executive Officer, President and Director |
| Dr. Richard A. Young Ph.D. | Founder and Independent Director |
| Kelly Gold | Chief Financial Officer |
| Dr. David Bumcrot Ph.D. | Chief Scientific Officer and Senior Vice President of Research |
| Dr. Leonard I. Zon M.D. | Founder |
| Caleb Moore | Chief Business Operations Officer and SVice President of Portfolio Strategy & Business Operations |
| Michelle Gates | Senior Vice President and Chief People Officer |
| Dr. Satya Kuchimanchi Ph.D. | Senior Vice President of Technical Operations |
| Dr. Daniel Tardiff Ph.D. | Vice President and Head of Discovery |
| Dr. Yuri Maricich M.B.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 7, 2025 | 8-K | Current Report |
| Nov 21, 2024 | 10-Q | Quarterly Report |
| Nov 21, 2024 | 8-K | Current Report |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 22, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 16, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 15, 2024 | 8-K | Current Report |